|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,344.00 GBX | +0.23% |
|
-1.24% | -3.23% |
| 05-07 | Fluicell nominates AstraZeneca executive to Board of Directors | FW |
| 05-07 | Nordic stocks in North America - Autoliv fell 0.6 percent | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.5 | 5.55 | 6.6 | 7.88 | 8.19 | |||||
Return on Total Capital | 5.42 | 7.95 | 9.52 | 11.53 | 11.93 | |||||
Return On Equity % | 0.42 | 8.63 | 15.64 | 17.59 | 22.84 | |||||
Return on Common Equity | 0.41 | 8.62 | 15.63 | 17.6 | 22.86 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 73.81 | 80.57 | 82.45 | 82.18 | 81.71 | |||||
SG&A Margin | 38.65 | 39.39 | 39.35 | 35.98 | 34.17 | |||||
EBITDA Margin % | 23.03 | 31.33 | 32.76 | 32.49 | 32.82 | |||||
EBITA Margin % | 21.09 | 29.41 | 31.17 | 31.01 | 31.33 | |||||
EBIT Margin % | 12.86 | 20.21 | 22.78 | 23.91 | 24.33 | |||||
Income From Continuing Operations Margin % | 0.31 | 7.42 | 13.01 | 13.02 | 17.42 | |||||
Net Income Margin % | 0.3 | 7.41 | 13 | 13.01 | 17.41 | |||||
Net Avail. For Common Margin % | 0.3 | 7.41 | 13 | 13.01 | 17.41 | |||||
Normalized Net Income Margin | 5.87 | 10.89 | 12.51 | 13.47 | 13.82 | |||||
Levered Free Cash Flow Margin | -2.4 | 27.88 | 20.74 | 15.65 | 13.39 | |||||
Unlevered Free Cash Flow Margin | -1.1 | 29.17 | 21.96 | 17.05 | 14.61 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.43 | 0.44 | 0.46 | 0.53 | 0.54 | |||||
Fixed Assets Turnover | 3.92 | 4.52 | 4.59 | 4.88 | 4.46 | |||||
Receivables Turnover (Average Receivables) | 7.61 | 6.7 | 5.87 | 6.47 | 6.34 | |||||
Inventory Turnover (Average Inventory) | 1.51 | 1.26 | 1.59 | 1.8 | 1.81 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.16 | 0.86 | 0.82 | 0.93 | 0.94 | |||||
Quick Ratio | 0.67 | 0.61 | 0.58 | 0.67 | 0.65 | |||||
Operating Cash Flow to Current Liabilities | 0.26 | 0.37 | 0.34 | 0.43 | 0.48 | |||||
Days Sales Outstanding (Average Receivables) | 47.98 | 54.49 | 62.22 | 56.55 | 57.6 | |||||
Days Outstanding Inventory (Average Inventory) | 242.25 | 289.7 | 229.78 | 203.39 | 201.16 | |||||
Average Days Payable Outstanding | 63.98 | 226.24 | 121.12 | 133.02 | 113.31 | |||||
Cash Conversion Cycle (Average Days) | 226.24 | 117.96 | 170.89 | 126.92 | 145.45 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 84.92 | 84.02 | 75.7 | 74.53 | 60.97 | |||||
Total Debt / Total Capital | 45.92 | 45.66 | 43.08 | 42.7 | 37.88 | |||||
LT Debt/Equity | 77.56 | 66.47 | 59.39 | 67.86 | 53.65 | |||||
Long-Term Debt / Total Capital | 41.94 | 36.12 | 33.8 | 38.88 | 33.33 | |||||
Total Liabilities / Total Assets | 62.71 | 61.59 | 61.27 | 60.71 | 57.29 | |||||
EBIT / Interest Expense | 6.2 | 9.77 | 8.56 | 9.22 | 10.47 | |||||
EBITDA / Interest Expense | 11.41 | 15.42 | 12.54 | 12.77 | 14.42 | |||||
(EBITDA - Capex) / Interest Expense | 10 | 14.23 | 11.42 | 11.39 | 12.36 | |||||
Total Debt / EBITDA | 3.77 | 2.2 | 1.94 | 1.7 | 1.51 | |||||
Net Debt / EBITDA | 3.05 | 1.76 | 1.56 | 1.39 | 1.22 | |||||
Total Debt / (EBITDA - Capex) | 4.3 | 2.39 | 2.13 | 1.91 | 1.76 | |||||
Net Debt / (EBITDA - Capex) | 3.47 | 1.91 | 1.71 | 1.56 | 1.42 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 40.58 | 18.53 | 3.29 | 18.03 | 8.63 | |||||
Gross Profit, 1 Yr. Growth % | 29.23 | 29.38 | 5.71 | 17.64 | 8.01 | |||||
EBITDA, 1 Yr. Growth % | 27.3 | 51.91 | 7.64 | 23.5 | 9.75 | |||||
EBITA, 1 Yr. Growth % | 29.82 | 54.85 | 9.07 | 24.26 | 9.74 | |||||
EBIT, 1 Yr. Growth % | 16.01 | 67.75 | 15.78 | 34.01 | 10.54 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -96.34 | 2.76K | 81.02 | 18.12 | 45.33 | |||||
Net Income, 1 Yr. Growth % | -96.5 | 2.84K | 81.11 | 18.14 | 45.34 | |||||
Normalized Net Income, 1 Yr. Growth % | 16.21 | 91.14 | 17.89 | 39.07 | 11.42 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -96.76 | 2.57K | 80.57 | 18.11 | 45.33 | |||||
Accounts Receivable, 1 Yr. Growth % | 58.46 | 19.58 | 16.57 | -1.25 | 23.31 | |||||
Inventory, 1 Yr. Growth % | 123.24 | -47.69 | 15.43 | -2.51 | 24 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 14.06 | -7.1 | 11.14 | 10.9 | 26.24 | |||||
Total Assets, 1 Yr. Growth % | 57.9 | -8.43 | 4.8 | 2.88 | 9.65 | |||||
Tangible Book Value, 1 Yr. Growth % | 34.63 | -4.44 | -14.02 | -8.31 | -40.16 | |||||
Common Equity, 1 Yr. Growth % | 151.36 | -5.68 | 5.69 | 4.2 | 19.32 | |||||
Cash From Operations, 1 Yr. Growth % | 24.26 | 64.48 | 5.48 | 14.65 | 22.88 | |||||
Capital Expenditures, 1 Yr. Growth % | 13.53 | 0 | 24.75 | 41.37 | 46.05 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -127.15 | -2.29K | -24.67 | -6.08 | -7.04 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -110.93 | -16.35K | -22.41 | -3.64 | -6.95 | |||||
Dividend Per Share, 1 Yr. Growth % | 2.5 | 1.05 | 0 | 6.9 | 3.23 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 23.87 | 29.08 | 10.65 | 10.42 | 13.23 | |||||
Gross Profit, 2 Yr. CAGR % | 18.9 | 29.31 | 21.92 | 11.55 | 12.73 | |||||
EBITDA, 2 Yr. CAGR % | 24.32 | 40.99 | 49.67 | 13.06 | 16.22 | |||||
EBITA, 2 Yr. CAGR % | 26.55 | 43.87 | 54.57 | 14.05 | 16.56 | |||||
EBIT, 2 Yr. CAGR % | 25.24 | 43.21 | 89.78 | 21.13 | 21.39 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -69.39 | 2.34 | 619.96 | 46.22 | 31.02 | |||||
Net Income, 2 Yr. CAGR % | -71.04 | 1.43 | 629.18 | 46.27 | 31.04 | |||||
Normalized Net Income, 2 Yr. CAGR % | 35.33 | 54.34 | 139.59 | 24.04 | 24.11 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -72.26 | -6.93 | 594.53 | 46.04 | 31.02 | |||||
Accounts Receivable, 2 Yr. CAGR % | 29.7 | 37.66 | 18.07 | 7.29 | 10.35 | |||||
Inventory, 2 Yr. CAGR % | 67.73 | 8.06 | -22.3 | 6.08 | 9.95 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 10.47 | 2.94 | 1.61 | 11.02 | 18.32 | |||||
Total Assets, 2 Yr. CAGR % | 31.02 | 20.25 | -2.03 | 3.84 | 6.21 | |||||
Tangible Book Value, 2 Yr. CAGR % | 9.23 | 13.43 | -9.35 | -11.21 | -25.93 | |||||
Common Equity, 2 Yr. CAGR % | 72.96 | 53.97 | -0.16 | 4.94 | 11.5 | |||||
Cash From Operations, 2 Yr. CAGR % | 41.72 | 42.96 | 31.71 | 9.97 | 18.7 | |||||
Capital Expenditures, 2 Yr. CAGR % | 5.57 | 6.55 | 11.69 | 32.8 | 43.69 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -62.01 | 89.55 | 126.88 | -17.68 | -6.72 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -75.22 | 82.08 | 150.11 | -15.26 | -5.47 | |||||
Dividend Per Share, 2 Yr. CAGR % | 1.24 | 1.77 | 0.52 | 3.39 | 5.05 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 19.2 | 22.07 | 19.84 | 13.06 | 9.82 | |||||
Gross Profit, 3 Yr. CAGR % | 16.24 | 22.29 | 20.91 | 20.47 | 10.36 | |||||
EBITDA, 3 Yr. CAGR % | 24.53 | 35.58 | 29.01 | 37.89 | 11.94 | |||||
EBITA, 3 Yr. CAGR % | 27.41 | 38.33 | 31.35 | 41.04 | 12.59 | |||||
EBIT, 3 Yr. CAGR % | 40.61 | 42.96 | 33.66 | 64.64 | 17.49 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -61.72 | 38.97 | 23.77 | 294.14 | 45.93 | |||||
Net Income, 3 Yr. CAGR % | -62.68 | 35.05 | 23.05 | 297.51 | 45.96 | |||||
Normalized Net Income, 3 Yr. CAGR % | 84.75 | 59.13 | 41.38 | 93.98 | 19.68 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -64.05 | 27.16 | 16.08 | 284.79 | 45.8 | |||||
Accounts Receivable, 3 Yr. CAGR % | 26.28 | 26.24 | 30.23 | 11.24 | 12.38 | |||||
Inventory, 3 Yr. CAGR % | 45.94 | 13.75 | 10.46 | -16.19 | 11.75 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 11.08 | 4.27 | 5.6 | 4.62 | 15.88 | |||||
Total Assets, 3 Yr. CAGR % | 20.21 | 16.27 | 14.86 | -0.42 | 5.74 | |||||
Tangible Book Value, 3 Yr. CAGR % | 2.93 | 4.47 | 3.42 | -9.01 | -22.15 | |||||
Common Equity, 3 Yr. CAGR % | 46.58 | 41.3 | 35.82 | 1.27 | 9.53 | |||||
Cash From Operations, 3 Yr. CAGR % | 31.57 | 48.93 | 29.18 | 25.76 | 14.12 | |||||
Capital Expenditures, 3 Yr. CAGR % | 1.51 | 3.68 | 12.3 | 20.82 | 37.08 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -37.65 | 25.78 | 40.28 | 66.13 | -14.28 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -53.76 | 24.52 | 37.12 | 78.98 | -12.58 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0.83 | 1.18 | 1.18 | 2.6 | 3.34 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.22 | 14.57 | 15.71 | 17.27 | 17.15 | |||||
Gross Profit, 5 Yr. CAGR % | 7.76 | 14.28 | 16.52 | 17.86 | 17.56 | |||||
EBITDA, 5 Yr. CAGR % | 7.2 | 18.26 | 27.46 | 25.8 | 22.5 | |||||
EBITA, 5 Yr. CAGR % | 7.4 | 19.15 | 30.2 | 27.75 | 23.9 | |||||
EBIT, 5 Yr. CAGR % | 4.26 | 19.45 | 43.23 | 33.33 | 26.74 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -49.22 | 2.8 | 23.8 | 41.83 | 26.62 | |||||
Net Income, 5 Yr. CAGR % | -49.76 | 1.84 | 22.54 | 39.43 | 26.19 | |||||
Normalized Net Income, 5 Yr. CAGR % | 4.88 | 25.34 | 75.1 | 43.47 | 31.98 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -50.87 | -2.3 | 17.52 | 34.4 | 21.84 | |||||
Accounts Receivable, 5 Yr. CAGR % | 18.48 | 20.81 | 22.93 | 18.29 | 21.88 | |||||
Inventory, 5 Yr. CAGR % | 30.94 | 9.14 | 13.42 | 10.62 | 10.26 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 8.23 | 4.41 | 7.19 | 6.92 | 10.52 | |||||
Total Assets, 5 Yr. CAGR % | 11 | 8.78 | 10.76 | 11.13 | 11.32 | |||||
Tangible Book Value, 5 Yr. CAGR % | -1.07 | -0.85 | -2.17 | -2.11 | -9.5 | |||||
Common Equity, 5 Yr. CAGR % | 21.46 | 19.88 | 25.71 | 25.45 | 25.52 | |||||
Cash From Operations, 5 Yr. CAGR % | 7.54 | 22.35 | 31.63 | 31.92 | 24.88 | |||||
Capital Expenditures, 5 Yr. CAGR % | -5.48 | -3.83 | 5.47 | 14.47 | 23.94 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -27.5 | 24.13 | 20.77 | 6.37 | 17.98 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -38.97 | 22.92 | 19.3 | 6.6 | 17.07 | |||||
Dividend Per Share, 5 Yr. CAGR % | 0.5 | 0.7 | 0.7 | 2.06 | 2.71 |
- Stock Market
- Equities
- AZN Stock
- Financials AstraZeneca PLC
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















